Should people with low blood counts get iron before open heart surgery?
Yes. In a trial of 955 anaemic adults, a single 1,000 mg dose of intravenous iron before heart surgery lowered the chance of needing a blood transfusion by about 10%, from 68.2% of patients down to 61.1%. Patients on iron also spent about one extra day alive and at home in the three months after surgery.
Anaemia means having too few red blood cells to carry oxygen well. It is common in people waiting for heart surgery, and it is a problem for a simple reason. Heart surgery causes blood loss, and someone who starts with a low red cell count has less to spare. That is why so many of these patients end up receiving donated blood.
Iron is the raw material the body uses to build red blood cells. Giving it through a vein delivers a large dose at once, which is useful when the gut absorbs iron poorly or when surgery is only weeks away. The question this trial set out to answer was whether topping up iron ahead of time actually changes what happens in the operating room and afterward.
What the data show
Red cell transfusions were the clearest result. Blood was given to 262 patients (61.1%) in the iron group and 302 patients (68.2%) in the placebo group during their hospital stay. That is about a 10% lower relative risk (relative risk 0.90), and in absolute terms roughly 7 fewer transfused patients for every 100 treated. Put another way, about 14 people need the infusion for one of them to avoid a transfusion they would otherwise have received. The result is very likely real, with a benefit somewhere between 1% and 18% lower risk (95% confidence interval 0.82 to 0.99), and less than a 3 in 100 chance it came down to coincidence (P=0.027).
The trial’s main measure was days alive and at home in the 90 days after surgery, which captures both survival and how quickly people get back to normal life. The median was 81.1 days on iron and 80.0 days on placebo, an adjusted difference of 1.0 day (95.4% confidence interval 0.0 to 2.1 days, P=0.041). That is a real but small gain, and the lower end of the range sits at zero. Major complications and length of hospital stay showed no difference between the groups.
Dr. Kumar’s Take
One extra day at home out of 90 is not the kind of number that changes a life. The transfusion result is the one worth paying attention to. Donated blood is a scarce resource, it carries its own risks, and every unit avoided is a real gain for a hospital system and for the patient receiving it. A single infusion that cuts the odds of needing blood by about a tenth is a reasonable trade for something so simple.
The honest read is that iron does not make heart surgery safer in the way people might hope. Major complications did not budge. Nobody left the hospital sooner. What changed is how much donated blood the operation consumed. That is a worthwhile target on its own, and it is the claim the data support.
How strong is the evidence?
This was a double blind, placebo controlled randomised trial, which is the strongest design available for this question. Neither the patients, their doctors, nor the people collecting the data knew who received iron and who received salt water. That matters here because transfusion decisions involve human judgment, and knowing a patient had been “topped up” could easily nudge a clinician one way or the other.
The trial ran at 33 hospitals across 10 countries, with participants enrolled between July 2016 and December 2023. Of 2,993 people screened, 955 were enrolled, and 921 of the eligible 939 were assessed for the main outcome. That spread of sites and that long enrollment window make the findings more likely to hold up in ordinary hospitals rather than just in specialised centres.
Who this applies to, and who it does not
Everyone in this trial had anaemia and was scheduled for elective heart surgery, meaning surgery planned in advance rather than done as an emergency. The iron was given anywhere from 1 to 26 weeks beforehand, so there was time for the body to use it. None of that applies to an emergency operation, where there is no window to prepare.
People with a haemoglobin disorder or an iron storage disorder were excluded, as were those on kidney dialysis and anyone who had received erythropoietin or intravenous iron in the previous four weeks. Iron overload is a real condition, and more iron is not automatically better. This trial tested correcting a deficit, not adding iron to people who already have enough.
Practical Takeaways
- If you are scheduled for elective heart surgery, ask whether your blood count has been checked well in advance, since this trial gave iron 1 to 26 weeks before the operation rather than the day before.
- Treat this as a way to reduce your odds of needing donated blood, not as a way to lower your risk of major complications, which did not change in this trial.
- Anaemia has causes worth finding, including blood loss from the gut, so an iron infusion should come alongside a search for why the count is low rather than instead of one.
- Do not start high dose iron on your own before surgery, because iron storage disorders and recent iron treatment were specific reasons people were kept out of this trial.
Related Studies and Research
- PPIs double iron deficiency risk: population study findings
- Treating gout properly may cut heart attack and stroke risk by up to 23%
- Pantoprazole shows no increased kidney risk in major trial
- Single-dose psilocybin vs placebo: first double-blind depression trial
FAQs
Why not just take iron pills before surgery instead of an infusion?
Iron tablets depend on the gut absorbing them, and absorption is slow and often incomplete, especially when inflammation is present. An infusion delivers the full dose directly into the bloodstream in one visit, which removes the guesswork about whether the body actually took it up. This trial tested a single 1,000 mg intravenous dose and did not compare it against oral iron, so it cannot tell you whether pills would have worked as well given enough lead time. The practical appeal of the infusion is that one appointment settles it.
Is avoiding a blood transfusion actually important if the blood is available?
Donated blood saves lives and is not something to refuse when it is needed. It is also a limited supply that depends on volunteers, and transfusion carries risks including reactions and, rarely, infection. Reducing how often patients need it protects the supply for the people who cannot avoid it. That is the logic behind patient blood management programs, and this trial gives them direct evidence that preoperative iron belongs in that toolkit.
Does this mean iron infusions will speed up recovery from heart surgery?
Not in any meaningful way. Patients on iron had a median of 81.1 days alive and at home out of 90, compared with 80.0 on placebo, a difference of about one day. Length of hospital stay did not differ between the groups, and neither did major complications. Anyone promising a faster recovery from an iron infusion is stretching well past what this evidence shows.
Bottom Line
In 955 anaemic adults having elective heart surgery at 33 hospitals in 10 countries, a single 1,000 mg intravenous iron infusion given 1 to 26 weeks beforehand reduced red cell transfusions from 68.2% of patients to 61.1%, about a 10% lower relative risk and roughly 7 fewer transfused patients per 100 treated. The gain in days alive and at home was one day out of 90, and major complications and hospital stay were unchanged. The case for preoperative iron rests on sparing donated blood, and on that measure the trial delivers.
